- 询价
- gelatins
- JLC163418
- 上海
- 2025年07月11日
- 人/动物/植物
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 克隆性：
多克隆
- 抗体名：
Anti-CDKL4 antibody
- 适应物种：
人/动物/植物
- 浓度：
0.8 mg/ml
- 保存条件：
-20°C
- 规格：
25 μl/100 μl/200 μl
Cat. No. JLC163418
Package 25 μl/100 μl/200 μl
Storage -20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
Product overview
Description Anti-CDKL4 rabbit polyclonal antibody
Applications ELISA, WB, IHC
Immunogen Synthetic peptide of human CDKL4
Reactivity Human, Mouse
Content 0.8 mg/ml
Host species Rabbit
Ig class Immunogen-specific rabbit IgG
Purification Antigen affinity purification
Target information
Symbol CDKL4
Full name cyclin dependent kinase like 4
Synonyms
Swissprot Q5MAI5
Target Background
Cell cycle progression is controlled in part by a family of cyclin proteins and cyclin dependent kinases (Cdks). Cdk proteins work in concert with the cyclins to phosphorylate key substrates involved in each phase of cell cycle progression. Another family of proteins, Cdk inhibitors, also plays a role in regulating the cell cycle by binding to cyclin-Cdk complexes and modulating their activity. Cdks are considered potential targets for anti-cancer therapy due to their involvement with cell cycle regulation. Cdks are also involved in the regulation of transcription and mRNA processing. CdkL4 (cyclin-dependent kinase-like 4) is a 315 amino acid protein that belongs to the CMGC Ser/Thr protein kinase family and may be involved in cell cycle regulation.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验a simple ELISA method to detect human anti-antibody response.
Purification Of Anti Peptide Antibody
antibody that could contribute to staining background. The proportion in each pool varies with the peptide immunogen. The quality of the anti-peptide serum seems to increase with multiple boosts - the first bleed may be feeble.
Anticardiolipin Antibody and Anti-beta 2 Glycoprotein I Antibody Assays
standard” laboratory test to diagnose or classify a patient as having APS. This chapter discusses the clinical and laboratory theoretical and technical aspects of aCL and anti-β2GPI antibody assays.
